Founded in 1964 as a way to encourage the “inventiveness” of the Hebrew University of Jerusalem’s staff, Yissum Research and Development Company seeks to support and encourage research, development and education in their efforts to turn science into commercial products for society. Yissum is charged with the not insignificant task of protecting HU’s inventions, products and technologies. Serving as the Technology Transfer Services for the university, Yissum focuses on the ongoing assessment, protection and commercial optimization of the university’s intellectual property.
In their 40-plus year history, Yissum has perhaps surpassed expectations, with reported annual revenues in excess of $40 million, mostly from royalties, and properties ranging from long-shelf-life tomatoes to treatments for cancer and Alzheimer’s disease, placing the Hebrew University in the world’s top 15 academic institutions as measured by revenues from intellectual property sales.
Protect, Partner, Perform
As the Technology Transfer University for HU, Yissum serves not only to protect the university’s intellectual properties, but also to partner with researchers and worldwide businesses to develop commercial markets, and through licensing, establishing companies, joint ventures and collaborative research, enhance the market value and performance of HU’s discoveries, increasing their availability to a global marketplace.
The arrangement has a track record of success. Hebrew University generates approximately $1 billion in annual sales from products in its IP base and Yissum represents over 250 licensed technologies and 60 spin-off companies. The numbers keep adding up with over 3,000 ongoing research projects, 1,200 researchers, 1,400 registered patents and 5 Nobel laureates, all representing 40% of Israel’s civilian scientific research. The range of intellectual properties includes a diverse mix of industrial and therapeutic areas, including biotechnology, nanotechnology, medical research and technologies, pharmaceuticals, agriculture and nutrition, water and environmental technologies, computer science and software development, homeland security and more.
The seemingly endless supply of promising research projects come from the university’s research base; supported by an annual budget of over $77 million, allowing Yissum to take advantage of Technology Transfer Opportunities by identifying appropriate commercial partners, negotiating license agreements, creating spin-off companies and working closely with local and global commercial partners.
Recent news items focus on the medical arena, with HU’s concept of using cellular technology to send X-rays and other medical diagnostics. The new technology would allow for the use of a smaller, less expensive and easier to use Data Acquisition Device (DAD) at remote patient sites, which would be connected via cell technology with advanced image reconstruction at a central site. The implications are far-reaching and could serve to bring advanced medical technology into areas that otherwise could not afford to have it at their disposal; bringing MRIs, X-Rays and other medical diagnostics into rural and third-world areas.
Technologies Supported
Reading through Yissum’s list of products and companies is like reading a Who’s Who directory of the medical and technological worlds. The lists are full of recognized names, successful products and companies that make headlines on a regular basis.
Products from Yissum include Alzheimer and dementia treatment Exelon, dry-eye treatments Cationorm and LO2A (Lacrycon, Dropyal), ovarian cancer treatment Doxil (Caeylx), UV-protection product UV-Pearls-already adopted by major companies for sunscreens and cosmetics, and a variety of other pharmaceutical products. Oh, remember those long-shelf-life tomatoes? That would thanks to BonTom Vegetable Breeding and Research Group, from HU, of course. Another agricultural product from Yissum and Hazera Genetics is the Ram Onion. On the software side, there is Making Better Career Decisions, an interactive, Internet based career-guidance and information system.
Looking over a partial list of companies shows even more diversity, touching on pharmaceuticals, biotech, agriculture and irrigation, water treatment, software development, safety, nanotechnology, and medical technologies, research, development and devices.
Water treatment technologies like En Gibton Ltd and Treatec 21 Industries Ltd; agricultural endeavors Leafsen Irrigation Systems Ltd, Kovax Ltd-vaccines for the aqua culture world, Avian Tech Ltd, and Ravgalai Ltd-detection of antibiotic residues in milk, meat and food products are just the start of the list. Technology and software development come into play with Ex Libris Ltd-high-performance applications for libraries, Mobileeye Vision Technologies Ltd-with automated, on-board driver assist systems and MusicGenome Inc-a system of identifying musical taste based on artificial intelligence.
Perhaps the heaviest area of development is in the medical and pharmaceutical arenas with a long list of companies researching and developing treatments for cancer-including Algen Pharmaceuticals Inc-basically “tricking” cancer cells into “committing suicide.” Other treatment technologies focus on infectious and autoimmune diseases, rheumatoid arthritis and improving the efficacy of vaccines; even delving into the “nutraceutical” field with carriers for nutraceuticals to be incorporated in food systems and cosmetic formulations.
Technology Transfer Services
Yissum serves the Hebrew University, protecting its intellectual properties and moving forward with innovations and technologies into commercial endeavors, ultimately, serving the world community as well as the university through applied chemistry, physics, life science and biotechnologies, water technologies, nanotechnologies, and even veterinary medicine and agricultural technologies. It’s easy to see why Yissum is so highly regarded in the scientific and academic communities and ranks among the top Technology Transfer Services in the world.
Mary Waltrip for http://www.yissum.co.il/. Serving as the Technology Transfer Services for the Hebrew University of Jerusalem, Yissum focuses on the ongoing assessment, protection and commercial optimization of the university’s intellectual property.

Search for newer technology has always fascinated researchers. Nano technology is a multidisciplinary field, which recently has emerged as one of the most propitious field in cancer treatment. Nano technology is definitely a medical boon for diagnosis, treatment and prevention of cancer disease. It supports and expands the scientific advances in genomic and proteomics and builds on our understanding of the molecular underpinnings of cancer and its treatment. The various nanotechnological approaches in cancer treatment have been encompassed in the current article. One of them includes localized delivery of heat and the localized imaging of biological materials through nanoparticles. The delivery may be in vitro or in vivo and is useful for the localized treatment of cancer and disorders involving over proliferation of tissue. Other approach relates to a novel process of manufacture of nanoparticles of substantially water insoluble materials from emulsions. These emulsions have the ability to form a single liquid phase upon dilution of the external phase, instantly producing dispersible solid nanoparticles. The formed nanoparticles can be used in a wide range of therapeutic treatments of cancer. Additional approach comprises of solid tumors having an acidic extra cellular environment and an altered pH gradient across their cell compartments. Nanoparticles responsive to the pH gradients are promising for cancer drug delivery. Such pH-responsive nanoparticles consist of a corona and a core, one or both of which respond to the external pH to change their soluble/insoluble or charge states, thereby they have therapeutic advantages over the conventional pH-insensitive counterparts. An alternative advancement discloses a method/system utilizing interaction of electromagnetic pulses or ultrasonic radiation with nano- and micro particles for enhancement of drug delivery in solid tumors. These particles can be attached to antibodies directed against antigens in tumor vasculature and selectively delivered to tumor blood vessel wall. A widespread understanding of these new technologies can provide essential breakthroughs in the fight against cancer.
Tiny man-made nanoparticles have been used to successfully smuggle a powerful cancer drug into tumor cells leaving healthy cells unharmed. When tested in mice, the Nan structure-based therapy was 10 times as effective at delaying tumor growth and far less toxic than the drug given alone. Researchers believe the therapy could transform many cancers from killer into chronic, treatable diseases.4,5 The major goals in designing nanoparticles as a delivery system are to control particle size, surface properties and release of pharmacologically active agents in order to achieve the site-specific action of the drug at the therapeutically optimal rate and dose regimen. Though liposome have been used as potential carriers with unique advantages including protecting drugs from degradation, targeting to site of action and reduction toxicity or side effects, their applications are limited due to inherent problems such as low encapsulation efficiency, rapid leakage of water-soluble drug in the presence of blood components and poor storage stability. On the other hand, polymeric nanoparticles offer some specific advantages over liposome. For instance, they help to increase the stability of drugs/proteins and possess useful controlled release properties. The purpose of the chemotherapy and radiation is to kill the tumor cells as these cells are more susceptible to the actions of these drugs and methods because of their growth at a much faster rate than healthy cells, at least in adults. Research efforts to improve chemotherapy over the past 25 years have led to an improvement in patient survival but there is still a need for improvement.6, 7 Current research areas include development of carriers to allow alternative dosing routes, new therapeutic targets such as blood vessels fueling tumor growth and targeted therapeutics that are more specific in their activity. Several nano biotechnologies mostly based on nanoparticles, have been used to facilitate drug delivery in cancer. The magic of nanoparticles mesmerizes everyone because of their multifunctional character and they have given us hope for the recovery from this disease. Although we are practicing better drug delivery paths into the body, we ultimately seek more accurate protocols to eradicate cancer from our society. This review will primarily address new methods for delivering drugs, both old and new, with a focus on nano particle formulations and ones that specifically target tumors.
Nitesh S Chauhan, M.Pharm., (Ph.D) Faculty of Pharmacy Editor in Chief International Journal of Pharmaceutical Sciences (IJPS) R R College of Pharmacy #67, R R Layout, Chikkabanavara Hesarghatta Main Road, Bangalore-560090 Tel: +918028391555, fax: +918028396210 Mob: +919986431757

Powered by Yahoo! Answers